Overview
Lobbying Costs
450,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
3.75 Fte (6)
Lobbyists with EP accreditation
2
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
Stichting Health Action International (HAI)
EU Transparency Register
44361352681-84 First registered on 30 Nov 2009
Goals / Remit
Health Action International is a non-profit, independent global network of consumer groups, public interest NGOs, healthcare professionals, academics, and individuals working and interested on pharmaceutical policy issues. HAI’s mission is to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.
In Europe, HAI has grown to become a pre-eminent voice in medicines policy intervention/discussion, supported by a strong European network of approximately 118 individual and organisation members from 20 European Union (EU) Member States and other non-EU countries. The HAI Europe projects team, based in Amsterdam, is responsible for coordinating the work programme and related activities within the European region. HAI monitors and advocates on EU policies that affect medicines on three key thematic priorities: Access to Needed Medicines, the Rational Use of Medicines, and the Democratisation of Medicines Policy. HAI’s work is carried out in collaboration with various stakeholders, including public health orientated NGOs, academia and other stakeholders. Targeted campaigns and activities are implemented to ensure that public awareness is raised with the aim to sensitise decision-makers in governments, EU institutions and general public to support policies that improve public health.Main EU files targeted
HAI advocates for policy initiatives that help to address current shortfalls/shortcomings on access to medicines. In Europe, HAI monitors EU initiatives with an impact on access to medicines, their rational use and on the democratisation of medicines policy. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: proposals EU cooperation on Health Technology Assessment; EUnetHTA; review of EU Orphan Regulation and orphan designation and other IP incentives; EU IP law and enforcement strategy; Supplementary Protection Certificate Regulation (manufacturing waiver and more) ; Competition policy; Euripid and other price sharing projects; EU trade agreements with impact on access to medicines; Horizon 2020’ Innovative Medicines Initiative and Horizon Europe; Multiannual Financial Framework (MFF); implementation One Health Action Plan against AMR; Clinical Trial Regulation; EMA's policies and activities; tackling medicines shortages; HAI also advocates for stricter regulations on pharmaceutical promotion in Europe specially among healthcare professionals and students.
Address
Head Office
Overtoom, 60/II
Amsterdam 1054HK
NETHERLANDS -
People
Total lobbyists declared
6
Employment time Lobbyists 100% 2 75% 1 50% 1 25% 2 Lobbyists (Full time equivalent)
3.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
2 accreditations were / are live (in bold) for the selected state of 14 Apr 2020
Name Start date End Date Ms Hannah VAN KOLFSCHOOTEN 14 Dec 2022 14 Dec 2023 Ms Janneke VAN OIRSCHOT 09 Dec 2022 09 Dec 2023 Mr Jaume VIDAL 04 Nov 2022 04 Nov 2023 Ms Ellie WHITE 27 Oct 2021 11 Feb 2022 Mr Jaume VIDAL 27 Oct 2021 27 Oct 2022 Mr Jaume VIDAL 19 Sep 2019 19 Sep 2020 Ms Ellie WHITE 14 Sep 2019 12 Sep 2020 Ms Ancel·la Santos Quintano 13 Oct 2018 25 Apr 2019 Mr Jaume VIDAL 13 Oct 2018 19 Sep 2019 Ms Ancel·la Santos Quintano 14 Oct 2017 13 Oct 2018 Mr Jaume VIDAL 20 Jul 2017 07 Jul 2018 Ms Tessel Mellema 07 Sep 2016 21 Jul 2017 Ms Ancel·la Santos Quintano 07 Sep 2016 07 Sep 2017 Ms Tessel Mellema 27 Aug 2015 26 Aug 2016 Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016 Ms Aliénor Devalière 27 Aug 2015 23 Jun 2016 Ms Ancel·la Santos Quintano 01 May 2014 05 Jun 2015 Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015 Mrs Aliénor Devalière 07 Jun 2014 27 Jan 2015 Ms Tessel Mellema 01 May 2014 05 Jun 2015 Mrs Ancel·la Santos Quintano 01 May 2014 27 Jan 2015 Ms Tessel Mellema 25 Jun 2013 01 May 2014 Mrs Ancel·la Santos Quintano 30 May 2013 01 May 2014 Ms Katrina Perehudoff 22 Sep 2012 17 Jun 2013 Ms Tessel Mellema 20 Sep 2012 25 Jun 2013 Complementary Information
HAI has two full-time policy advisors that are solely focused on our EU projects. They are supported by Admin, Communications, PME & our Executive Director.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition, Health Systems Advocacy partnership, Global Snakebite Initiative, Medicines Transparency Alliance (MeTA). In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.
HAI is also a member of the EMA’s Patients and Consumers Working Party (PCWP) and the HTA Network Stakeholder Pool.
HAI is in official relations with the WHO and collaborates with the organisation on several projects as well as attending governing bodies and ad-hoc meetings.Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
450,000€
EU grant income for closed financial year
236,335 € (Source: CHAFEA)
Other financial info
All our funding sources have been described in section B.
HAI’s accounting and financial reporting is subject to an annual independent audit, the outcomes of which are reported to the Foundation Board and published on HAI’s website (see http://haiweb.org/governance/policies-plans-reports/ )
HAI maintains a strict independence policy to avoid conflicts of interest. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
For our publications please visit: http://haiweb.org/publications-page/
For our press releases and other news please visit: https://haiweb.org/news/
In 2020 HAI brought to a close its four-year campaign on transparency in the Netherlands, Our Medicines Our Right. The campaign aimed to raise public awareness in The Netherlands and urge Dutch politicians to take action and increase transparency of price and R&D costs of medicines. You can find out more about the campaign here: www.ourmedicinesourright.eu, and about our closing stunt here: https://haiweb.org/pharmaceutical-companies-secrecy/.Other examples of our policy implementation and communications work are our work with the London School of Economics on the risk of bias in clinical trials for cancer drugs (https://haiweb.org/cancer-drug/) and our advocacy work in the European Parliament (https://haiweb.org/what-we-do/hais-work-with-the-epwg-on-access-to-medicines-and-poverty-related-diseases/).Other activities
HAI is a member of the European Medicines Agency Patients' and Consumers' Working Party (PCWP); and a member of the HTA Network Stakeholder Pool.
- Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 07 Oct 2021 Location video conference Subject COVID Vaccines Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
Other Lobbyists -
Date 03 Jun 2021 Location video-conference Subject Trade in relation to COVID-related technologies Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Cristina Rueda Catry (Cabinet member)
- Caroline Boeshertz (Cabinet member)
Other Lobbyists -
Date 15 May 2018 Location Brussels Subject Access to medicines in poor countries Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Maria Asenius (Cabinet member)
- Pedro Velasco Martins (Cabinet member)
Other Lobbyists -
Date 15 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - International Diabetes Federation European Region
- ASDM Consulting
- European Public Health Alliance
- EUROPEAN ORGANISATION FOR RARE DISEASES
- European Patients' Forum (EPF)
- Bureau Européen des Unions de Consommateurs
- European Cancer Patient Coalition
- European Federation of Allergy and Airways Diseases Patients' Associations
-
Date 18 Oct 2016 Location Brussels Subject Access to medicines Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Meetings